ELOXX PHARMACEUTICALS, INC. Research and Development in Process
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Research and Development in Process of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-31
- ELOXX PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-12-31 was $0.00.
- ELOXX PHARMACEUTICALS, INC. research and development in process for the quarter ending 2022-09-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. research and development in process for the quarter ending 2021-12-31 was $0.00.
- ELOXX PHARMACEUTICALS, INC. research and development in process for the quarter ending 2021-09-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. research and development in process for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. research and development in process for fiscal 2021 was $22.67M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $22.67M derived: sum of 3 quarters · filed 2023-03-31 | $22.67M 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $22.67M derived: sum of 2 quarters · filed 2022-11-10 | $22.67M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $22.67M 10-Q · filed 2022-08-12 | $22.67M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |